French biopharma company InnaVirVax scores $4 mln
InnaVirVax, a French biopharmaceutical company focused on treating infectious and chronic diseases, has closed its third funding round at $4 million. The company's investors include the FCPR CapDecisif 2, G1J Ile-de-France, Pradeyrol Development, Fa Dièse and FRCI.
17 July 2015•4 mins read
